



Certification of Substances Department

Certificate of suitability No. R0-CEP 2021-154 - Rev 00

- 1 Name of the substance:
- 2 GLYCOPYRRONIUM BROMIDE
- 3 Name of holder:
- 4 HAINAN POLY PHARMACEUTICAL COMPANY LIMITED
- 5 Guilinyang Economic Development Area
- 6 Meilan District
- 7 China-571 127 Haikou, Hainan Province
- 8 Site(s) of production:
- 9 SEE ANNEX 1
- 10 After examination of the information provided on the manufacturing method and subsequent
- processes (including purification) for this substance on the site(s) of production listed in annex, we
- 12 certify that the quality of the substance is suitably controlled by the current version of the
- monograph **GLYCOPYRRONIUM BROMIDE** no. 1783 of the European Pharmacopoeia, current
- 14 edition including supplements.
- In the last steps of the synthesis acetone and ethanol are used as solvents. Their residual
- content is limited by the test for loss on drying described in the monograph, with a limit of not
- 17 more than 0.5%.
- A risk management summary for elemental impurities has been provided. (Annex 2)
- The re-test period of the substance is 24 months if stored in double polyethylene-aluminium
- 20 bags, placed in a fibre drum.
- The holder of the certificate has declared the absence of use of material of human or animal
- origin in the manufacture of the substance.
- 23 The submitted dossier must be updated after any significant change that may alter the quality,
- 24 safety or efficacy of the substance.
- 25 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice
- and in accordance with the dossier submitted.

- 27 Failure to comply with these provisions will render this certificate void.
- 28 This certificate is granted within the framework of the procedure established by the European
- 29 Pharmacopoeia Commission [Resolution AP-CSP (07) 1] for a period of five years starting from
- 30 16 November 2022. Moreover, it is granted according to the provisions of Directive 2001/83/EC
- and Directive 2001/82/EC and any subsequent amendment, and the related guidelines.
- 32 This certificate has two annexes of 1 page each.
- 33 This certificate has:
- 34 lines.

On behalf of the Director of EDQM

Strasbourg, 16 November 2022

DECLARATION OF ACCESS (to be filled in by the certificate holder under their own responsibility)

HAINAN POLY PHARMACEUTICAL COMPANY LIMITED, as holder of the certificate of suitability

R0-CEP 2021-154 - Rev 00 for Glycopyrronium bromide

hereby authorises

(name of the pharmaceutical company)

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): (name of product(s) and marketing number(s), if known)

The holder also certifies that no significant changes to the operations as described in the SEP dossier have been made since the granting of this version of the certificate.

Date and Signature (of the CEP holder):





Certification of Substances Department

Annex 1: Site(s) of production for R0-CEP 2021-154 - Rev 00

Production of intermediate(s):

ANHUI POLY PHARMACEUTICAL COMPANY LIMITED No.58 Xiahong Road Hi-tech Industrial Development Zone China-246 000 Anging, Anhui Province

Production of Glycopyrronium bromide:

HAINAN POLY PHARMACEUTICAL COMPANY LIMITED Guilinyang Economic Development Area Meilan District China-571 127 Haikou, Hainan Province

Elemental impurities

Risk assessment results of elemental impurities in Glycopyrronium Bromide

Element	Class	Intentionally added?	Considered in risk management?	Conclusion
Cd	1	No	Yes	Absent*
Pb	1	No	Yes	Absent
As	1	No No	Yes	Absent
Hg	1	No	Yes	Absent
Со	2A	No	Yes	Absent
V	2A	No	Yes	Absent
Ni	2A	No	Yes	Absent
Tl	2B	No	No	N/A
Au	2B	No	No	N/A
Pd	2B	No so so s	No	N/A
Ir	2B	No %	No No	N/A
Os	2B	No	No	N/A
Rh	2B	No	No	N/A
Ru	2B	No	No	N/A
Se	2B	No	No	N/A
Ag	2B	No	No	N/A
Pt	2B	No	No	N/A
Cr	3	No	Yes	Absent
Cu	3	No	Yes	Absent
Mo	3	No	Yes	Absent
Sb	3	No	Yes	Absent
Li	3	No	Yes	Absent
Ba	3	No	No No	N/A
Sn	3	No	No No	N/A
Mg	Others	Yes	Yes	<300 ppm
Ti	Others	No	Yes	< 300 ppm

Note: * Absent: less than 30% ICH Q3D Option 1 limit.